The Diagnostic Value of Hybrid PET/MR for Systemic Amyloidosis
The Diagnostic Value of Hybrid PET/MR for Systemic Amyloidosis
Systemic amyloidosis is a multi-system disease caused by extracellular deposition of
 insoluble amyloid fibrils in various tissues and organs, leading to progressive organ
 dysfunction. The clinical manifestations of different types of amyloidosis are complex and
 diverse, and the prognosis is very poor. Early detection and classification of amyloid
 deposition is becoming increasingly important. However, conventional imaging techniques
 including ultrasound and magnetic resonance are not sensitive or specific. Endocardial biopsy
 is the gold standard for the diagnosis of cardiac amyloidosis, but it is an invasive
 procedure with a clinical complication rate of 6%.

 Positron emission tomography (PET) provides a valuable tool for diagnosing systemic
 amyloidosis. Recently, amyloid PET imaging agents (11C-PIB or 18F-florbetapir) have been
 shown to be effective as novel positron tracers to detect potential amyloid deposition in
 some small sample studies. The investigators will use the most advanced imaging equipment,
 integrated PET/MR with amyloid PET imaging agents(11C-PIB or 18F-florbetapir) to image
 patients suspected or confirmed systemic amyloidosis, the aim is to explore the value of
 hybrid PET/MR for systemic amyloidosis.
Systemic amyloidosis is a multi-system disease caused by extracellular deposition of
 insoluble amyloid fibrils in various tissues and organs, leading to progressive organ
 dysfunction. The clinical manifestations of different types of amyloidosis are complex and
 diverse, and the prognosis is very poor. Early detection and classification of amyloid
 deposition is becoming increasingly important. However, conventional imaging techniques
 including ultrasound and magnetic resonance are not sensitive or specific. Endocardial biopsy
 is the gold standard for the diagnosis of cardiac amyloidosis, but it is an invasive
 procedure with a clinical complication rate of 6%.

 Positron emission tomography (PET) provides a valuable tool for diagnosing systemic
 amyloidosis. Recently, amyloid PET imaging agents (11C-PIB or 18F-florbetapir) have been
 shown to be effective as novel positron tracers to detect potential amyloid deposition in
 multiple organs in some small sample studies. The investigators will use the most advanced
 imaging equipment, integrated PET/MR with amyloid PET imaging agents(11C-PIB or
 18F-florbetapir) to image patients suspected or confirmed systemic amyloidosis, the aim is to
 explore the value of hybrid PET/MR for systemic amyloidosis.

 For patients suspected of or diagnosed with systemic amyloidosis, the investigators aim to
 evaluate the roles of hybrid PET/MR in differential diagnosis, detecting the deposition of
 amyloid in various tissues and organs of the body, guiding biopsy, and determining treatment
 plan prior to treatment; for the patients with a history of systemic amyloidosis, the aim is
 to evaluate the value of hybrid PET/MR for treatment response assessment.
Inclusion Criteria:

 Patient with Monoclonal Ganunopathy, adds one of the following criteria:

 -  Histologically confirmed Amyloidosis of any organ.

 -  Average left ventricular thickness of the echocardiogram is more than 11 mm without
 uncontrolled high blood pressure.

 -  12-lead ECG shows unexplained low voltage <0.5 mV.

 Exclusion Criteria:

 -  Patient can not lie flat

 -  NYHA Level 4 Heart Failure

 -  Patient is pregnant or nursing

 -  Patient is allergic to amyloid PET imaging agents

 -  Patient with acute systemic diseases and electrolyte disorders

 -  Patient with severe claustrophobia or unstable vital sigh

 -  Other serious comorbidities evaluated by primary investigator